Business context and reporting period
CapsoVision, Inc. filed this Form 8-K for an event dated September 25, 2026. The company announced the event on September 28, 2026. CapsoVision’s common stock trades on Nasdaq under the symbol CV.
Material event
The FDA cleared AI Highlights™, an AI-assisted reading feature for the CapsoCam Plus® system, on September 25, 2026. The company’s September 28 press release was filed as Exhibit 99.1 and incorporated by reference.
Financial results and outlook
This filing reports no revenue, profit, cash flow, margin, debt, liquidity, or other financial results. It provides no financial guidance or outlook.
Investor facts to verify
- Review Exhibit 99.1 for details about the FDA clearance, the feature, and any stated commercialization plans.
- Check subsequent filings and disclosures for the clearance’s expected financial or operational impact; this 8-K does not quantify one.